UBS Resumes Buy Rating on Regeneron Amid Undervaluation of Dupixent Potential
UBS has resumed a 'Buy' rating for Regeneron Pharmaceuticals (REGN), citing that the market is underestimating the value of follow-on developments to its blockbuster drug, Dupixent. The Swiss bank highlighted both the potential expansion of Dupixent's exclusivity and ongoing development efforts as key undervalued aspects. Regeneron’s Dupixent has been a major revenue driver in dermatology and asthma treatments, with UBS suggesting that current market assumptions do not fully reflect its long-term growth prospects. The bank emphasized Regeneron’s strong R&D pipeline and the likelihood of extended patent protection for Dupixent as significant catalysts. The upgrade reflects confidence in Regeneron's ability to maintain a competitive edge through innovation, despite ongoing pressures from biosimilars and generic competition.
Topics: Dupixent Pharmaceuticals Stock Analysis